

DOI: [10.4081/mrm.2020.662](https://doi.org/10.4081/mrm.2020.662)

**Characterization and burden of severe eosinophilic asthma in New Zealand:
Results from the HealthStat Database**

Sumitra Shantakumar,¹ Yu-Fan Ho,¹ Janine Beale,² Barry Gribben³

¹Department of Real World Evidence and Epidemiology, GlaxoSmithKline, GSK Asia House, Singapore

²Department of Medical Affairs, GlaxoSmithKline, GSK Auckland, New Zealand

³CBG Health Research, Auckland, New Zealand

Corresponding author: Barry Gribben, CBG Health Research, PO Box 45173, Te Atatu Peninsula, Auckland, 0651, New Zealand. E-mail: barry.gribben@cbg.co.nz

Supplementary Table 1. Asthma control and exacerbations in the 12-month baseline period.

Items	Non-SEA (n=3116)	SEA (n=160)	Total (n=3276)
History of exacerbations, n (%)			
0	2183 (70.1)	-	2183 (66.7)
1	550 (17.7)	-	550 (16.8)
2	190 (6.1)	57 (35.6)	247 (7.5)
3	85 (2.7)	37 (23.1)	122 (3.7)
≥4	49 (1.6)	21 (13.1)	70 (2.1)
Patients with controlled asthma*	2733 (87.7)	-	2733 (83.4)
Patients with uncontrolled asthma*	383 (12.3)	160 (100)	543 (16.6)
No. of exacerbations, mean±SD	0.6±1.3	3.8±2.2	0.7±1.5
No. of GP visits, mean±SD	14.0±9.3	22.0±14.2	14.4±9.8


*Patients experiencing ≥2 exacerbations in the baseline period were considered to have uncontrolled asthma; patients with <2 exacerbations were considered to have controlled asthma. GP: general practice, SD: standard deviation, SEA: severe eosinophilic asthma.

Supplementary Table 2. Respiratory medication usage during the 12-month baseline period.

Items	Non-SEA (n=3116)	SEA (n=160)	Total (N=3276)
Percentage of days covered[‡] by prescription for asthma treatment, %	20.6	45.2	-
No. of prescriptions, mean			
Any oral corticosteroids	0.6	3.8	0.7
Any single LABA	0.1	0.0	0.1
Any single ICS	0.8	0.1	0.7
Any single LAMA	0.0	0.1	0.0
SABD	1.2	1.8	1.2
Combined ICS + LABA	0.8	1.8	0.8
Antibiotics	0.2	0.6	0.2
Total	3.6	8.1	3.8
Treatment use, % (mutually exclusive categories)			
None	0.3	0	0.3
ICS alone	52.0	0	49.4
ICS/LABA	42.6	93.8	45.1
ICS/LAMA	0.2	0	0.2
LABA	0.3	0	0.3
ICS/LABA/LAMA	1.2	4.4	1.3
LAMA	0.1	0	0.1
SABD alone	3.4	1.9	3.3


[‡]Assuming 90 days of coverage for each prescription. ICS: inhaled corticosteroid, LABA: long-acting β-agonist, LAMA: long-acting muscarinic antagonist, SABD: short-acting bronchodilator, SEA: severe eosinophilic asthma.

Supplementary Figure 1. Data obtained from the HealthStat database in the baseline and follow-up periods.



*the baseline period did not include the index date. GP, general practice; HCRU, healthcare resource utilization.

Supplementary Figure 2. Stratification by ethnicity of the subgroup of total asthma patients by: A – those who experienced ≥ 4 exacerbation in the 12-month baseline period and those on high-dose ICS + LABA, and B – by blood eosinophil count.



ICS: inhaled corticosteroid, LABA: long-acting β -agonist.